Johnson & Johnson $JNJ Stock Sold by Generate Investment Management Ltd

Key Points

• Generate Investment Management cut its Johnson & Johnson stake by 15.7% in the third quarter, selling 17,386 shares and retaining 93,579 shares valued at approximately $24.8 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson reported third-quarter adjusted EPS of $2.59, exceeding estimates, while revenue increased 5.9% to $25.4 billion. Management raised 2026 guidance to $101.0–$101.4 billion in revenue and $11.05–$11.15 in adjusted EPS.
• The company declared a quarterly dividend of $1.34 per share, equivalent to a 2.1% yield, while analysts maintain a “Moderate Buy” consensus with an average price target of $273.61. Risks include slower MedTech growth, litigation-related charges and potential pressure from new drug deals.

Generate Investment Management Ltd decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 15.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 93,579 shares of the company's stock after selling 17,386 shares during the period. Johnson & Johnson comprises 1.0% of Generate Investment Management Ltd's portfolio, making the stock its 23rd largest holding. Generate Investment Management Ltd's holdings in Johnson & Johnson were worth $24,774,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Silver Coast Investments LLC boosted its position in Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock valued at $271,000 after purchasing an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV lifted its holdings in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after buying an additional 39 shares during the last quarter. Triumph Capital Management lifted its holdings in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after buying an additional 39 shares during the last quarter. Kwmg LLC grew its stake in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company's stock valued at $631,000 after buying an additional 39 shares in the last quarter. Finally, Denali Advisors LLC lifted its stake in Johnson & Johnson by 1.2% in the second quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock valued at $839,000 after acquiring an additional 40 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm's stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 87,569 shares of company stock worth $23,064,544 in the last three months. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reported third-quarter adjusted EPS of $2.59, ahead of the $2.53 consensus, while revenue rose 5.9% year over year to approximately $25.4 billion. Innovative Medicine revenue grew 7.9%, supported by oncology, immunology and strong TREMFYA sales. Johnson & Johnson Q3 Earnings Surpass Estimates
• Positive Sentiment: Management raised its 2026 outlook to revenue of $101.0 billion-$101.4 billion and adjusted EPS of $11.05-$11.15. The improved outlook and pharmaceutical growth provide fundamental support for the stock. Johnson & Johnson reports Q3 2026 results and raises guidance
• Positive Sentiment: Royal Bank of Canada maintained an “outperform” rating and set a $280 price target. Although the target was reduced from $290, it still implies meaningful upside from recent trading levels. Johnson & Johnson analyst coverage
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, maintaining JNJ’s appeal as a defensive income investment. Johnson & Johnson quarterly dividend announcement
• Neutral Sentiment: JNJ is reportedly considering a mid-2027 spinoff of its hips-and-knees orthopedics business. The move could sharpen the company’s focus, but its benefits and execution risks remain uncertain. J&J considers hips-and-knees spinoff
• Negative Sentiment: MedTech growth of roughly 2.5% missed expectations, with weakness in surgery and cardiovascular products, particularly outside the United States. Investors remain concerned that pharmaceutical strength is masking slower device-market performance.
• Negative Sentiment: Reported profit was sharply reduced by special charges tied to the proposed talc litigation resolution and recent business-development activity. Management also warned that new drug deals may weigh on 2027 earnings, while Erste Group lowered its FY2027 EPS estimate to $12.65 from $12.83.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $3.85 during mid-day trading on Wednesday, reaching $252.46. The company had a trading volume of 4,045,485 shares, compared to its average volume of 7,973,307. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a market cap of $608.39 billion, a price-to-earnings ratio of 29.25, a PEG ratio of 2.70 and a beta of 0.21. The company has a 50 day moving average of $265.89 and a 200-day moving average of $249.37. Johnson & Johnson has a 52 week low of $184.66 and a 52 week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business's revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.09 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson's payout ratio is currently 62.11%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent research reports. UBS Group set a $270.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a research report on Wednesday, July 15th. Guggenheim reiterated a "buy" rating and set a $287.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 7th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b+)" rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $273.61.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.